Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04613206 · ClinicalTrials.gov registry record · Phase 2
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
A Phase 2 study of Influenza and Immunization; Infection, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
- 1
- Study location
NCT04613206: Active Phase 2 study of Influenza and Immunization; Infection, sponsored by Vanderbilt University Medical Center.
NCT04613206 is a Phase 2 study of Influenza and Immunization; Infection that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 396 participants, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04613206, a Phase 2 study of Influenza and Immunization; Infection, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
- 1
- Study location
Study Summary
The influenza virus is a significant cause of morbidity in adult solid organ transplant (SOT) recipients. However, these individuals show a suboptimal response to vaccines including the standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. The first study compared HD-IIV vs. SD-IIV in adult SOT and noted HD-IIV was safe and reported higher immunogenicity; however, the median post-transplant period was 38 months. In another phase II trial of adult SOT recipients, two doses of SD-IIV a month apart compared to one-dose SD-IIV revealed increased immunogenicity, with a median post-transplantation period of 18 months. Therefore, these studies lack evaluation in the early post-transplantation period in this vulnerable population when influenza disease is most severe. The administration of two-doses of HD-IIV in the same influenza season has also not been studied in SOT recipients. Moreover, the vast majority of SOT influenza vaccinations studies have not substantively evaluated prolonged immunogenicity. Thus, the optimal immunization strategy for SOT recipients less than 12 months post-transplant is poorly-defined. In addition, the immunologic predictors and correlates of influenza vaccine immunogenicity in SOT recipients have not been defined. The investigators hypothesize that adult solid organ transplant recipients that are 1-11 months out from transplant and are receiving high-dose inactivated influenza vaccine will have higher hemagglutination inhibition (HAI) geometric mean titers to influenza A antigens compared to adult SOT recipients receiving standard-dose inactivated influenza vaccine. To test this hypothesis and address the above critical knowledge gaps, The investigators propose to conduct a phase II multicenter
Primary Outcome
Antibody titers will be measured by hemagglutination inhibition assay.
Conditions Studied
Interventions
- BIOLOGICAL Standard Dose Quadrivalent Inactivated Influenza Vaccine
- BIOLOGICAL High Dose Quadrivalent Inactivated Influenza Vaccine
Study Locations (1)
Tennessee
- Vanderbilt Univeristy Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT04613206 still lists
NCT04613206 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Standard Dose Quadrivalent Inactivated Influenza Vaccine is the first listed.
NCT04613206 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04613206 about?
NCT04613206 is a clinical study titled "High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients". The influenza virus is a significant cause of morbidity in adult solid organ transplant (SOT) recipients. However, these individuals show a suboptimal response to vaccines including the standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcom...
What is the current status of trial NCT04613206?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2021-01-11. Estimated completion is 2026-12-31.
What conditions does trial NCT04613206 study?
This clinical trial studies the following conditions: Influenza, Immunization; Infection, Solid Organ Transplant, Transplantation Infection.
What interventions are being tested in trial NCT04613206?
The interventions under investigation include: Standard Dose Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL), High Dose Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04613206?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04613206 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04613206's enrollment target sits among peer trials
396 54th of 156 higher than 103 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI